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ABSTRACT 
The most frequent cancer type in females in the world is breast cancer; with a lifetime risk of the order of 1/10.Breast cancer is the most 
common invasive cancer in females. It usually presents with a lump in the breast with or without other manifestations. The tumor is 
malignant (cancer) if the cells can grow into (invade) surrounding tissues or spread (metastasize) to distant areas of the body. Breast 
cancers can start from different parts of the breast. Our understanding of the molecular events relating to breast cancer biology and 
pathogenesis has greatly increased over the last decade. Diagnosis of breast cancer depends on physical examination, mammographic 
findings and biopsy results. Treatment of breast cancer depends on the stage of the disease. Lines of treatment include mainly surgical 
removal of the tumor followed by radiotherapy or chemotherapy. Second lines including immunotherapy and other therapy and alternative 
medicine may represent a hope for breast cancer patients. 
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Breast cancer is the most common cancer form in women; 
in the countries with highest incidence rates, the lifetime 
risk of developing breast cancer is over 10%. Although 
breast cancer has a better prognosis than many other 
cancer forms, with 10‐year relative survival rates of up to 
80% in some countries, the burden of breast cancer 
remains considerable. As a result of improved treatments, 
more and more patients are cured, while others will live on 
with stable disease for a long time. However, much 
remains to be done and can be done in a combined 
approach to increase the early detection and treatment of 
breast cancer and optimise care organisations to further 
improve outcomes [1]. For example, survival still differs 
considerably between countries that appear to have 
comparable economic and human resources dedicated to 
healthcare. This highlights a key discrepancy in cancer care 
and calls for the further assessment of best practices in 
prevention and treatment and the adaption of such across 
countries. Although survival is the most important 
measure of outcomes in breast cancer, quality of life should 
also be included as an important marker, as the care the 
patient experiences impacts greatly on their psychological 
and physical well being as well as on their socio‐economic 
situation. Over the last 30 years, major paradigm shifts in 
the treatment and organisation of breast cancer care 
include: the implementation of programmes for early 
detection using mammography; the introduction of 
adjuvant treatment such as endocrine therapy, 
chemotherapy and adjuvant radiotherapy following 
surgical treatment in breast cancer; and the 
implementation of multidisciplinary care. The change in 
surgical procedures from mastectomy (total removal of the 
breast) to more localised excision of tumours 
complemented by sentenial node biopsy, which makes it 
possible to fine‐tune further treatment, is an important 
example of how quality of life has been improved without 
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compromising survival. In recent years, targeted biological 
therapies such as trastuzumab, for the treatment of early 
as well as metastatic breast cancer, have resulted in further 
improvement of outcomes [1]. 
TYPES OF BREAST CANCER 
Breast cancer is generally considered to be a highly 
heterogeneous cancer type [2], encompassing distinct 
phenotypic and morphological profiles, and thus possess 
very different clinical behaviors [3]. Clinically, breast 
cancers are characterized into three basic types based on 
their immunohistochemical (IHC) properties (hormone 
status). They are hormone receptor-positive, HER2 
positive (HER2+), and triple negative breast cancers. 
Hormone receptor-positive are the breast cancers with 
estrogen receptor-positive (ER+)/progesterone receptor-
positive (PR+). Approximately 85% of all breast cancers 
are hormone receptor-positive. They can be treated with 
hormone therapies, including tamoxifen and the aromatase 
inhibitors, anastrozole (Arimidex), letrozole (Femara) or 
exemestane (Aromasin). Hormone receptorpositive breast 
cancers can be further divided into two subtypes: Luminal 
A and Luminal B. Luminal A tumors tend to be ER+ and/or 
PR+, and HER2-negative (HER2-). Luminal B tumors tend 
to be ER+ and/or PR+, and HER2+ (or HER2- with high 
Ki67). HER2+ refers to breast cancer that is human 
epidermal growth factor receptor 2 positive but hormone 
receptor-negative. About 20% of all breast cancers are 
HER2+. This type of breast cancer can be treated using 
anti-HER2 drugs, such as trastuzumab (Herceptin). Triple-
negative breast cancers, also called basal-like subtype, 
refers to any breast cancer that does not express the genes 
for estrogen receptor, progesterone receptor or HER2 
receptor. Triple-negative breast cancers account for 
around 15% of all breast cancer population. Since this type 
of breast cancer does not overexpresses receptors, 
targeting therapies are not helpful. Clinically, this type is 
treated with a combination of surgery, radiation therapy 
and chemotherapy. Other than these three major types, 
there are some minor molecular subtypes that are less 
characterized, such as luminal C subtype, normal breast-
like subtype [4-6]. 
EPIDEMIOLOGY OF BREAST CANCER 
Incidence and mortality Worldwide: Globally, over one 
million women are diagnosed with breast cancer every 
year. It is the most frequently diagnosed cancer in women1 
and the leading cause of cancer death in women. Every 
year more than 500,000 women die from the disease [7, 8]. 
Lifetime risk of breast cancer On average one in eight 
women will develop breast cancer in their lifetime. This is 
double the risk of developing lung cancer, the second most 
common cancer in women [9]. 
Prognosis Cancer statistics often use an ‘overall 5 year 
survival rate’ to give a better idea of the longer term 
outlook for people with a particular cancer. It is almost 
impossible to predict how long an individual patient might 
live, but 5 year survival rates can give an approximate 
range. The 5 year survival rate describes on average the 
‘amount’ of people that will be alive 5 years after diagnosis. 
The average 5 year survival rate for women with early 
stage breast cancer is 81%.However; on average only 35% 
of women with late or advanced stage breast cancer 
currently survive for 5 years [10]. 
RISK FACTORS FOR BREAST CANCER [11] 
Genetic factors: Genetic factors are known to be involved 
in increasing the risk of a number of cancers, including 
breast cancer. A woman’s inherited genetic profile impacts 
her risk of developing breast cancer. Approximately 5-10% 
of breast cancers are attributable to genetic factors. The 
most common breast cancer susceptibility genes are 
BRCA1, BRCA2, PTEN (Cowden syndrome), and TP53 (Li-
Fraumeni syndrome). Research continues to explore 
additional susceptibility genes, as well as gene-
environment interactions. Each child of a parent with a 
mutation has a 50% chance of inheriting the mutation. For 
persons with BRCA1 or BRCA2 mutations, the estimated 
risks of developing breast cancer by 70 years of age is 
about 55-65% (BRAC1) and 45-47% (BRAC2). BRCA1 and 
BRCA2 mutations can be inherited from either parent. 
Genetic mutations may vary by ethnic group, for example, 
studies of women in sub-Saharan Africa, Asia, and Latin 
America identified variable rates of BRCA1 and BRCA2 
mutations ranging from 0.5-18% when testing moderate-
to high-risk populations. Genetic testing requires both 
laboratory expertise and genetic counseling services, 
which are often not available in low-resource settings. 
Family history of breast cancer: One’s risk of developing 
breast cancer increases with the number of affected first-
degree relatives. This is thought to be due to a combination 
of factors, both inherited (although not a specific gene) and 
environmental.  
Personal history of breast cancer: For women with a 
personal history of breast cancer (DCIS or invasive breast 
cancer) there is an increased risk of developing a second 
breast cancer in either the same breast or the opposite 
breast (estimates suggest a 4% increase over 7.5 years). 
Exposure to therapeutic ionizing radiation: Exposure to 
ionizing therapeutic radiation of the chest at a young age 
(highest risk if exposed at 10-14 years of age) increases 
one’s risk; however, the risk of developing decreases 
dramatically if radiation is administered after age 40. For 
example, therapeutic radiation at a young age for 
treatment of Hodgkin lymphoma is associated with an 
increased risk of breast cancer. However, there are no data 
to suggest that current radiation therapy practices 
administered as part of breast cancer treatment, (i.e., 
radiation therapy after lumpectomy) increases the risk for 
developing a second breast cancer. Additionally, 
mammography and chest x-rays do not appear to increase 
breast cancer risk.  
Hormonal and reproductive factors: Endogenous 
hormones (hormones produced within the body’s cells), 
particularly estrogen exposure, play a role in breast cell 
growth and proliferation. Elevated or prolonged 
endogenous estrogen levels are associated with an 
increase risk of breast cancer in post-menopausal women. 
Known risk factors for breast cancer are associated with 
reproductive factors which extend natural exposure to 
hormones produced by the ovaries such as early onset of 
menstruation, late onset of menopause, later age of first 
pregnancy (i.e., over 30 years of age) and never having 
given birth. Laboratory evidence also suggests that higher 
levels of other endogenous hormones, (such as insulin and 
insulin-like growth factor (IGF), may play a role in breast 
cancer development. 
Therapeutic or exogenous estrogen hormones: The use 
of prolonged hormone replacement therapy (HRT) after 
menopause has been associated with an increased risk of 
breast cancer. In a large randomized trial, women who 
took the combination of estrogen and progesterone for 
Pawar et al                                                                                                   Journal of Drug Delivery & Therapeutics. 2018; 8(6-A):135-140  
ISSN: 2250-1177                                                                                  [137]                                                                                 CODEN (USA): JDDTAO 
more than 5 years after menopause had an increased risk 
of being diagnosed with breast cancer. It is now 
recommended that HRT should be used only for specific 
indications (such as significant menopausal symptoms) 
and the duration of treatment should be limited. 
Age: The risk of breast cancer increases with age and in 
some high-resource settings in populations that have a 
long life expectancy the lifetime risk could be as high as 1 
in 8 women. The impact of age on breast cancer incidence 
in LMICs is less well studied, but becomes increasingly 
important as life expectancy improves. 
Weight (obesity): An association between obesity and 
breast cancer risk is thought to be at least partially related 
to the role of fat cells in contributing to levels of circulating 
hormones and other factors. Adiposity (fat cell volume) can 
affect circulating hormones as estrogen precursors are 
converted to estrogen in fat cells. Women’s estrogen levels 
also vary based on their menopausal status, so the effect of 
obesity on breast cancer risk may depend on the 
menopausal status of the woman, with post-menopausal 
women being more affected than premenopausal women. 
Some experts suggest that up to 20% of breast cancer 
cases could be avoided by increasing physical activity and 
avoiding weight gain.  
Alcohol consumption: Harmful use of alcohol is associated 
with an increased risk of breast cancer. Experts suggest 
that up to 14% of breast cancers could be avoided by 
substantially reducing or eliminating harmful use of 
alcohol. 
PATHOGENESIS (HORMONE SENSITIVE) BREAST 
CANCER  
Gene expression in breast carcinomas Two different 
types of estrogen receptors exist, alpha (α) and beta (β) 
(ERα and ERβ respectively). Various tissues express these 
receptors with breast, ovaries and the endometrium 
expressing ERα, while the kidneys, brain, lungs and several 
other organs expressing ERβ. The role of ERβ in 
carcinogenesis remains controversial whereas, a clear 
contribution of ERα protein has been established. Both ER 
subtypes carry a DNA binding domain and exist in the 
nucleus and the cytosol.  When estrogen enters the cell, it 
binds the ER and the complex migrates into the nucleus 
and leads to the production of transcription proteins that 
induces changes in the cell.  Therefore, due to estrogen’s 
proliferative properties, its cellular stimulation can have 
negative consequences in patients expressing large 
quantities of these receptors intracellularly[12,13]. 
Role of estrogen in breast cancer progression and 
development Two major hypotheses attempt to explain 
the tumorigenic effects of estrogen: (i) genotoxic effects of 
estrogen metabolites via generation of radicals (initiator) 
and (ii) the hormonal properties of estrogen inducing 
proliferation of cancers as well as the premalignant cells 
(promoter) [12,13].. 
Role of Human Epidermal Growth Factor Receptor 2 
(HER2) HER2 belongs to the epidermal growth factor 
receptor (EGFR) family of proto-oncogenes and currently 
is not known to have a ligand.  However, the protein has 
been shown to form clusters within the cell membranes in 
malignant breast tumours. Its mechanism of 
carcinogenesis remains largely unknown, but 
overexpression is associated with rapid tumour growth, 
shortened survival, increased risk of recurrence after 
surgery, and poor response to conventional 
chemotherapeutic agents [12, 13]. 
SIGNS AND SYMPTOMS OF BREAST CANCER 
The most common symptom of breast cancer is a new 
lump or mass. A painless, hard mass that has irregular 
edges is more likely to be cancer, but breast cancers can be 
tender, soft, or rounded. They can even be painful. For this 
reason, it is important to have any new breast mass, lump, 
or breast change checked by a health care professional 
experienced in diagnosing breast diseases. Other possible 
symptoms of breast cancer include:  
• Swelling of all or part of a breast (even if no distinct 
lump is felt) 
• Skin irritation or dimpling (sometimes looking like an 
orange peel) 
• Breast or nipple pain 
• Nipple retraction (turning inward) 
• Redness, scaliness, or thickening of the nipple or 
breast skin 
• Nipple discharge (other than breast milk) 
Sometimes a breast cancer can spread to lymph nodes 
under the arm or around the collar bone and cause a lump 
or swelling there, even before the original tumor in the 
breast is large enough to be felt. Swollen lymph nodes 
should also be checked by a doctor [14,15]. 
DIAGNOSIS OF BREAST CANCER  
Physical examination of the breasts by a healthcare 
provider and mammography are considered as the 
primary tools for diagnois of breast cancer [16]. Fine 
needle aspiration and cytologycan also help to establish 
the diagnosis with a good degree of accuracy. Other types 
of biopsy include core biopsy or an excisional biopsy, in 
which the entire lump is removed. Imaging techniques 
such as ultrasound, computed tomography or magnetic 
resonance imaging are sufficient to give the physician 
accurate diagnosis and staging of the disease [17]. 
PREVENTION OF BREAST CANCER  
Proper control of body weight, drinking less alcohol, 
physical exercises and breastfeeding are valuable 
measures for reduction of the risk of breast cancer. Also, 
dietary consumption of omega-3 polyunsaturated fatty 
acids and soya beans appears to reduce the risk [18]. The 
selective estrogen receptor modulators (such as 
tamoxifen) reduce the risk of breast cancer but increase 
the risk of thromboembolism and endometrial cancer. 
They are recommended only for prevention of breast 
cancer in women at high risk. The benefit of breast cancer 
reduction continues for at least five years after stopping 
these medications [19]. 
MANAGEMENT OF BREAST CANCER  
Management of breast cancer depends on many factors 
including the stage of the cancer and the age of the patient. 
Breast cancer is usually treated with surgery, which may 
be followed by chemotherapy or radiation therapy, or both 
(Figure 1). Hormone receptor-positive cancers are often 
treated with hormone-blocking therapy over several years. 
Monoclonal antibodies or other immunomodulators may 
be given in advanced stages with distant metastasis [20]. 
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Figure 1: Lines of treatment of breast cancer 
•Surgery Depending on the stage and type of the tumor, 
just lumpectomy may be all that is necessary, or removal of 
larger amounts of breast tissue may be necessary. Surgical 
removal of the entire breast is called mastectomy [21]. A 
mastectomy involves removing all of the breast tissue, 
sometimes along with other nearby tissues. Before 
lumpectomy, a needle-localization of the lesion with 
placement of a guidewire may be performed. However, 
mastectomy may be the preferred treatment in multifocal 
cancer, breast previously treated with radiotherapy, large 
tumor relative to the size of the breast and if the patient 
has any disease of the connective tissue which may 
complicate radiotherapy. During the operation, the lymph 
nodes in the axilla are also considered for removal. If the 
removed tissue does not have clear margins, further 
removal of a part of the pectoralis major muscle may be 
needed [22]. 
•Radiotherapy Radiation therapy is treatment with 
high‐energy rays or particles that destroy cancer cells. This 
treatment may be employed to kill any cancer cells that 
remain in the breast, chest wall, or lymph node areas after 
breast‐conserving surgery. Radiotherapy has gained an 
increased importance, and a recent meta‐analysis revealed 
that radiotherapy as a complement to surgery decreased 
the risk of loco‐regional relapse by two‐thirds compared to 
surgery alone [23].External beam radiation is the most 
common type of radiation therapy for women with breast 
cancer. If breast‐conservation surgery was performed, the 
entire breast receives radiation, and sometimes an extra 
boost of radiation is given to the area in the breast where 
the cancer was removed to prevent it from coming back in 
that area. The purpose of radiation is to reduce the chance 
of recurrence. Radiation therapy involves using high-
energy X-rays or gamma rays that target a tumor or tumor 
site. This radiation is very effective in killing cancer cells 
that may remain after surgery or recur where the tumor 
was removed [24]. 
•Chemotherapy Chemotherapy may be used before 
surgery, after surgery, or instead of surgery for inoperable 
cases. Patients with estrogen receptor positive tumors will 
receive hormonal therapy after chemotherapy is 
completed. Systemic chemotherapy is delivered through 
the bloodstream to reach cancer cells throughout the body. 
Chemotherapy for breast cancer may be given through an 
intravenous (IV) tube placed into a vein or as a pill or 
capsule that is swallowed (orally). Patients may have 
treatment once a week, once every 2 weeks (also called 
dose-dense chemotherapy), once every 3 weeks, or even 
once every 4 weeks. Common drugs for breast cancer 
include: Cisplatin (Platinol) Cyclophosphamide (Neosar) 
Docetaxel (Docefrez, Taxotere) Doxorubicin (Adriamycin) 
Epirubicin (Ellence) Eribulin (Halaven) Fluorouracil (5-FU, 
Adrucil) Gemcitabin(Gemzar) Ixabepilone 
(Ixempra)Methotrexate (multiple brand names) Paclitaxel 
(Taxol)Pegylated liposomal doxorubicin (Doxil)Protein-
bound paclitaxel (Abraxane)Vinorelbine (Navelbine). The 
side effects of chemotherapy depend on the individual, the 
drug(s), the schedule, and the dose used. In general, side 
effects include fatigue, risk of infection, nausea and 
vomiting, hair loss, loss of appetite, and diarrhea. These 
side effects can often be prevented or managed during 
treatment, and they usually go away once treatment has 
finished. Rarely, long-term side effects may occur, such as 
heart or nerve damage or secondary cancers [25]. 
•Hormonal therapy For women with ER- or PR-positive 
breast cancer, hormonal therapy, also called endocrine 
therapy, is typically recommended. Because these types of 
tumors use hormones to fuel their growth, blocking the 
hormones can help prevent recurrence and death, either 
by itself or following adjuvant or neoadjuvant 
chemotherapy. Hormonal therapy is also effective as a 
treatment for metastatic breast cancer, shrinking the 
cancer and improving cancer-related symptoms [26].  
Tamoxifen (Nolvadex, Soltamox) Tamoxifen blocks 
estrogen from attaching to breast cancer cells. It is effective 
at reducing the risk of recurrence in the breast that had 
cancer, the risk of developing cancer in the other breast, 
and the risk of distant recurrence. It is also approved to 
reduce the risk of breast cancer in women at high risk for 
developing the disease and for reducing local recurrence 
for women with DCIS who had a lumpectomy The side 
effects of tamoxifen include hot flashes; vaginal dryness, 
discharge, or bleeding. Very rare risks include a cancer of 
the lining of the uterus, cataracts, and blood clots. 
However, tamoxifen improves bone health and cholesterol 
levels and can be effective for both premenopausal and 
postmenopausal women [26]. 
Aromatase inhibitors (AIs) Drugs such as anastrozole 
(Arimidex), exemestane (Aromasin), and letrozole 
(Femara) decrease the amount of estrogen made by tissues 
other than the ovaries in postmenopausal women. 
Research shows that all 3 AI drugs work equally well and 
have similar side effects, which may include muscle and 
joint stiffness and pain, hot flashes, vaginal dryness, an 
increased risk of osteoporosis and broken bones, and 
higher cholesterol levels. Women who have not yet gone 
through menopause should not take AIs because they do 
not block the effects of estrogen made by the ovaries. 
Often, doctors will monitor blood estrogen levels in women 
whose periods have recently stopped, or whose periods 
stop with chemotherapy, to make sure the ovaries are no 
longer producing this hormone [26]. 
Ovarian suppression Stopping the ovaries from making 
estrogen is one of the oldest hormonal treatments for 
hormone receptor-positive breast cancer and for 
premenopausal women with metastatic breast cancer. 
Medications called gonadotropin or luteinizing releasing 
hormone (GnRH or LHRH) analogues stop the ovaries from 
making estrogen, causing temporary menopause. Goserelin 
(Zoladex) and leuprolide (Lupron) are drugs given by 
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injection under the skin that stop the ovaries from making 
estrogen for 1 to 3 months. Most commonly, these drugs 
are given with tamoxifen or AIs as part of adjuvant therapy 
for breast cancer. Less commonly, they are given alone. 
Surgical removal of the ovaries, called an oophorectomy, 
may also be considered for some patients; however, the 
hormonal effects of this surgery are permanent [26].  
•Targeted therapy Targeted therapy is a type of drug 
treatment that targets the cancer’s specific genes, proteins, 
or the tissue environment that contributes to cancer 
growth and survival. This type of treatment blocks the 
growth and spread of cancer cells while limiting damage to 
healthy cells.Research studies show that not all breast 
tumors have the same targets. To find the most effective 
treatment, your doctor may run specialized tests to 
identify genes, proteins, and other factors specific to your 
tumor. The first targeted therapies used to treat breast 
cancer were hormonal therapies. Then HER2 targeted 
therapies were approved to treat HER2-positive breast 
cancer [27].  
HER2 Targeted Therapy If your cancer is HER2 positive, 
your doctor may recommend medications that only affect 
HER2-positive cancer cells. These anti-HER2 treatments 
block HER2 to stop the growth of cancer cells.  
Trastuzumab (Herceptin) Trastuzumab is approved for 
the treatment of HER2-positive breast cancer. Currently, 
patients with stage I to stage III breast cancer typically 
receive a trastuzumab-based regimen, often including a 
combination of trastuzumab with chemotherapy, followed 
by completion of one year of adjuvant trastuzumab. 
Patients receiving trastuzumab have a small (2% to 5%) 
risk of heart problems, and this risk is increased if a patient 
has other risk factors for heart disease. These heart 
problems may go away and can be treatable with 
medication. Trastuzumab is also an important part of 
treatment for metastatic HER2-positive breast cancer [28]. 
 Pertuzumab (Perjeta) Pertuzumab is approved as part of 
neoadjuvant treatment for breast cancer in combination 
with trastuzumab and chemotherapy. It is also used in 
combination with trastuzumab and chemotherapy for 
metastatic HER2-positive breast cancer [29]. 
Ado-trastuzumab emtansine or T-DM1 (Kadcyla) T-DM1 
is a combination of trastuzumab linked to a type of 
chemotherapy. This allows the drug to deliver 
chemotherapy into the cancer cell while reducing the 
chemotherapy received by healthy cells. T-DM1 is 
approved to treat metastatic breast cancer [30].  
 Lapatinib (Tykerb) Lapatinib is approved for the 
treatment of metastatic HER2positive breast cancer. It may 
be given in combination with capecitabine or with 
letrozole [30].  
Neratinib (Nerlynx) This oral drug is approved as a 
treatment for higher-risk HER2-positive, early-stage breast 
cancer. It is taken for a year, starting after patients have 
finished 1 year of trastuzumab [31]. 
•Immunotherapy The immune system can fightmany 
types of tumors including breast cancer.A new clinical trial 
is designed to use oncofetal antigen (OFA) to recruit the 
patient's ownimmune system to target and attack the 
cancer cells to improve patient survival and quality of life. 
Each patient will receive three monthly injections of the 
patient's own dendritic cells that have been sensitized to 
OFA. It is anticipated that once the sensitized cells are 
injected back into the patient, the patient's T-cells will 
locate the OFA found on the patient's cancer cells, thereby 
generating an immune response with killing of the cancer 
cells and preventing further spread of the disease. 
Stimuvax is a therapeutic cancer vaccine designed to 
induce an immune response to cancer cells that express 
MUC1, a glycoprotein antigen over-expressed on most 
cancers. Stimuvax is thought to work by stimulating the 
body's immune system to identify and destroy cancer cells 
expressing MUC1[32].  
•Thermochemotherapy Medifocus heat treatment added 
to chemotherapy increased the median tumor shrinkage in 
the thermochemotherapy arm to 88.4%, while for 
chemotherapy alone the median tumor shrinkage was 
58.8%. For the thermo-chemotherapy treatment arm, 
almost 80% of breast tumors had a tumor volume 
reduction of 80% or more, compared to only 20% for the 
chemotherapy alone [32]. 
•Alternative and Adjunctive Treatments Recent studies 
have begun treating women suffering from breast cancer 
with a procedure known as cryoablation. The treatment 
freezes, than defrosts tumors using small needles so that 
only the harmful tissue is damaged and ultimately dies. 
The advantage of this technique includes alternative to 
surgery, limiting hospital visits and reducing scarring [32]. 
Also, traditional herbal medicine was used as adjunctive 
therapy for treatment of breast cancer. They were proven, 
in combination with conventional therapy, to improve 
quality of life and decrease the number of hot flashes per 
day [33]. Other lines of alternative therapy include group 
support therapy, cognitive behavioral therapy, cognitive 
existential group therapy, a combination of muscle 
relaxation training and guided imagery, thymus extract, 
transfer factor and melatonin. Encouraging but not fully 
convincing results were found for melatonin [34]. 
•Medicinal Plants in Breast Cancer Therapy Among 
Complementary and alternative medicines, herbal 
medicine is the most commonly used group of treatment. 
Herbal treatment is the oldest used system of medicine in 
the world with more than 2000 years history. Other names 
used for herbal therapy are phytomedicine, phyto-therapy 
or botanical medicine. phytoconstituents resulting from 
the herbs such as Vinca rosea, Taxus species, Allium 
sativum, Aloe vera, Angelica sinensis, Astragals 
membranaceus, Glycine max, Glycyrrhiza glabra, Hordeum 
vulgare, Hydrocotyle asiatica, Medicago sativa, Morinda 
citrifolia, Panax pseudoginseng, Saussurea lappa, Taxus 
wallichiana, Tinospora cordifolia, Viscum album, Withania 
somnifera, Zingiber officinale etc. have been used in 
numerous preparations to improve function of the body’s 
immune cells that stimulates production of cytokines 
including interleukin, interferon, tumor necrosis factor as 
well as colony stimulating factor. These preparations assist 
the body to battle cancer more efficiently and also decrease 
the harmful side effects of chemotherapy and radiotherapy 
[35]. 
CONCLUSION  
Breast cancer represents one of the most common tumors 
in females worldwide. Its early diagnosis is the first step 
for effective treatment. Treatment regimen should consist 
of combination therapy to achieve high cure rate and 
decrease the risk of recurrence. 
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